Sophia Abene

A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.

Updates from June 24, 2024, on FDA-issued food recalls highlight potential issues such as Listeria contamination, mold growth, and undeclared allergens.

The study analyzed over 15 years shows declining rates of chronic and acute Hepatitis B in China, which is expected to make a significant contribution to the global elimination of hepatitis B by 2030.

Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of Cdifficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.

Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.

Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.

Michigan is taking decisive action to support dairy farms affected by the recent outbreak of highly pathogenic avian influenza (HPAI).

FDA approves pneumococcal vaccine V116, Salmonella outbreak linked to a household pet, Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome, and more this week from Contagion.

Snapchill coffee products recalled over botulinum toxin concerns.

Understanding the evolving trends in antibiotic resistance among S aureus infections, commonly treated empirically with oral non–β-lactam antibiotics, is essential for guiding effective treatment strategies.

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.

Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects.

In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated Clostridioides difficile infections.

Jerry Krishnan, MD, PhD, working with NASEM, examines the multifaceted challenges of defining Long COVID as they introduce a unified definition for this persistent condition.

Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.

While the global clinical pipeline for antibacterial treatments displays notable activity, it remains inadequate to address the challenges of antimicrobial resistance.

Tailored for adults, V116's effectiveness covers serotypes linked to 84% of invasive pneumococcal disease in those 50+, outperforming existing vaccines in immune response rates.

Bearded dragon pets carrying this illness and infecting their loving caregivers create a significant public health concern.

Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome (STSS), a severe and often fatal bacterial infection.

In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.

Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.

The latest data from the Gonococcal Antimicrobial Susceptibility Surveillance, calls for updated treatment protocols and intensified surveillance measures to address this escalating concern effectively.

With no observed mortality or adverse outcomes, this research sheds light on effective treatments for combating the pandemic in younger populations.

BWC0977 has strong potential to effectively target the priority pathogens needed to address public health concerns.

Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.

Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offering insights into microbiota alteration and prospects for management.

Exact estimates of hospitalization and fatality rates for SARS-CoV-2 are rare among populations without previous exposure, particularly within demographic subgroups.

Innovative approach across opioid treatment programs bridges geographical barriers, achieving cure rates, and unlocking health benefits for underserved populations.

Historically, pneumococcal vaccination in adults has been reserved for those at heightened risk, with adults bearing the cost compared to free childhood vaccinations.

The FDA alerts against certain apricot seed products containing amygdalin, a potentially harmful compound, and the CDC highlights Salmonella outbreaks, underlining the necessity for proper hygiene and poultry handling.